Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis

Abstract EN

The relative efficacy of different strategies for chronic hepatitis B (CHB) patients with lamivudine resistance (LAM-R) has not yet been systematically studied.

Clinical trials were searched in PUBMED, MEDLINE, EMBASE, and CNKI databases up to February 15, 2016.

Nine trials including 764 patients met the entry criteria.

In direct meta-analysis, TDF showed a stronger antiviral effect than any one of ETV, LAM/ADV, and ADV against LAM-R hepatitis B virus.

LAM/ADV therapy was superior to ADV in suppressing viral replication.

ETV achieved similar rate of HBV DNA undetectable compared to ADV or LAM/ADV.

In network meta-analysis, TDF had higher rates of HBV DNA undetectable compared to ETV (OR, 24.69; 95% CrI: 5.36–113.66), ADV (OR, 37.28; 95% CrI: 9.73–142.92), or LAM/ADV (OR, 21.05; 95% CrI: 5.70–77.80).

However, among ETV, ADV, and LAM/ADV, no drug was clearly superior to others in HBV DNA undetectable rate.

Moreover, no significant difference in the rate of ALT normalization or HBeAg loss was observed compared the four rescue strategies with each other.

TDF appears to be a more effective rescue therapy than LAM/ADV, ETV, or ADV.

LAM plus ADV therapy was a better treatment option than ETV or ADV alone for patients with LAM-R.